Cargando…

Rectal Transmission of Transmitted/Founder HIV-1 Is Efficiently Prevented by Topical 1% Tenofovir in BLT Humanized Mice

Rectal microbicides are being developed to prevent new HIV infections in both men and women. We focused our in vivo preclinical efficacy study on rectally-applied tenofovir. BLT humanized mice (n = 43) were rectally inoculated with either the primary isolate HIV-1(JRCSF) or the MSM-derived transmitt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chateau, Morgan L., Denton, Paul W., Swanson, Michael D., McGowan, Ian, Garcia, J. Victor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603991/ https://www.ncbi.nlm.nih.gov/pubmed/23527295 http://dx.doi.org/10.1371/journal.pone.0060024

Ejemplares similares

Human Breast Milk and Antiretrovirals Dramatically Reduce Oral HIV-1 Transmission in BLT Humanized Mice
por: Wahl, Angela, et al.
Publicado: (2012)

Systemic Administration of Antiretrovirals Prior to Exposure Prevents Rectal and Intravenous HIV-1 Transmission in Humanized BLT Mice
por: Denton, Paul W., et al.
Publicado: (2010)

Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice
por: Denton, Paul W, et al.
Publicado: (2008)

Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression
por: Romas, Laura, et al.
Publicado: (2016)

A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate
por: Yang, Kuo-Hsiung, et al.
Publicado: (2014)

Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel
por: Cranage, Martin, et al.
Publicado: (2008)

The humanized BLT mouse to study HIV transmission
por: Deruaz, M, et al.
Publicado: (2012)

Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1
por: Nijmeijer, Bernadien M., et al.
Publicado: (2019)

Hypogammaglobulinemia in BLT Humanized Mice – An Animal Model of Primary Antibody Deficiency
por: Martinez-Torres, Francisco, et al.
Publicado: (2014)

Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques
por: Dobard, Charles W, et al.
Publicado: (2015)

Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction
por: Foster, Toshana L., et al.
Publicado: (2016)

Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4(+)CD8(+) thymocytes
por: Zou, Wei, et al.
Publicado: (2012)

Differential Contribution of BLT(1) and BLT(2) to Leukotriene B(4)-Induced Human NK Cell Cytotoxicity and Migration
por: Wang, Meng, et al.
Publicado: (2015)

Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma
por: Kumar, Amit, et al.
Publicado: (2018)

Intestinal epithelial BLT1 promotes mucosal repair
por: Hayashi, Shusaku, et al.
Publicado: (2022)

Correlation between Compartmental Tenofovir Concentrations and an Ex Vivo Rectal Biopsy Model of Tissue Infectibility in the RMP-02/MTN-006 Phase 1 Study
por: Richardson-Harman, Nicola, et al.
Publicado: (2014)

Transmission of Multiple HIV-1 Subtype C Transmitted/founder Viruses into the Same Recipients Was not Determined by Modest Phenotypic Differences
por: Song, Hongshuo, et al.
Publicado: (2016)

Two distinct forms of human BLT2: long-form and short-form BLT2
por: Wei, Jun-Dong, et al.
Publicado: (2023)

Mucosal effects of tenofovir 1% gel
por: Hladik, Florian, et al.
Publicado: (2015)

Characterization of the roles of Blt1p in fission yeast cytokinesis
por: Goss, John W., et al.
Publicado: (2014)

Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir
por: García-Lerma, J. Gerardo, et al.
Publicado: (2008)

A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)
por: Mcgowan, Ian, et al.
Publicado: (2013)

High-power pseudospark and BLT switches
por: Frank, K, et al.
Publicado: (1988)

High-power pseudospark and BLT switches
por: Frank, K, et al.
Publicado: (1988)

Correction: Mucosal effects for tenofovir 1% gel
por: Hladik, Florian, et al.
Publicado: (2015)

Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques
por: Makarova, Natalia, et al.
Publicado: (2022)

A sequestered fusion peptide in the structure of an HIV-1 transmitted founder envelope trimer
por: Ananthaswamy, Neeti, et al.
Publicado: (2019)

HIV-1 subtype C transmitted founders modulate dendritic cell inflammatory responses
por: Lumngwena, Evelyn Ngwa, et al.
Publicado: (2020)

Identification of Unequally Represented Founder Viruses Among Tissues in Very Early SIV Rectal Transmission
por: Chen, Jian, et al.
Publicado: (2018)

Sexually-Transmitted/Founder HIV-1 Cannot Be Directly Predicted from Plasma or PBMC-Derived Viral Quasispecies in the Transmitting Partner
por: Frange, Pierre, et al.
Publicado: (2013)

Biochemical Characterization of Three BLT Receptors in Zebrafish
por: Okuno, Toshiaki, et al.
Publicado: (2015)

Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome
por: Song, Hongshuo, et al.
Publicado: (2012)

Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes
por: Salazar-Gonzalez, Jesus F., et al.
Publicado: (2016)

In vitro replicative fitness of early Transmitted founder HIV-1 variants and sensitivity to Interferon alpha
por: Ashok kumar, Manickam, et al.
Publicado: (2020)

Sexually transmitted founder HIV-1 viruses are relatively resistant to Langerhans cell-mediated restriction
por: Hertoghs, Nina, et al.
Publicado: (2019)

Generation and characterization of infectious molecular clones of transmitted/founder HIV-1 subtype C viruses
por: Luthuli, Bonisile, et al.
Publicado: (2023)

Differences in Tumor Growth and Differentiation in NSG and Humanized-BLT Mice; Analysis of Human vs. Humanized-BLT-Derived NK Expansion and Functions
por: Kaur, Kawaljit, et al.
Publicado: (2022)

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
por: Goonetilleke, Nilu, et al.
Publicado: (2009)

Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes
por: O’Brien, Sean P., et al.
Publicado: (2019)

Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted / founder sensitivity to broadly neutralizing antibodies
por: Ratnapriya, Sneha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_me25gc6nk612p6p7fa7475afdi